580 research outputs found
Electrochemical Performance of Grids of Lead-acid Batteries made from Pb-0.8%Ca-1.1%Sn Alloys Containing Cu, As and Sb Impurities in the presence of phosphoric acid
Electrochemical performance of grids of lead-acid Batteries manufactured from Pb-0.8%Ca-1.1%Sn alloys containing Cu, As and Sb impurities at 0.1 wt% level were studied in 4.0 M H2SO4 without and with 0.4 M H3PO4. The presence of impurities in the alloy or addition of H3PO4 was found to suppress the corrosion rate. H3PO4 increased the rates of both hydrogen and oxygen evolution reactions at high overpotentials for all alloys. Except for Cu-containing alloy, H3PO4 had a slight positive effect on PbO2 formation.The self-discharge of PbO2 under polarization or opencircuitconditions increased in the presence of H3PO4 but the positive grid corrosion decreased, except for the As-containing alloy. Impurity-containing alloys showed significantly lower self-discharge rate in the presence of H3PO4 than in its absence. Impedance measurement was able to detect and quantify the formation of the highly insulating inner PbO layer beneath the outer PbSO4 layer and its transformation to the conducting PbO2, during the oxidation of alloys under constant current conditions.H3PO4 significantly enhanced the formation of PbO in thepresence of impurities, especially Sb
GINGER ETHANOLIC EXTRACT, GINGER OIL OR RICE BRAN OIL INDUCED HEPATOPROTECTIVE EFFECT AGAINST FATTY LIVER IN RATS
Hepatoprotective effect of ethanol extract of ginger, ginger oil or rice bran oil against fatty liver disease which induced by ethanol stress was investigated in the present study. Thirty six (36) male albino rats were classified into 6 groups as follows: 1- Normal control (NC), 2- Positive control (induced fatty liver by ethanolic stress) (PC+), 3- rats group administered ethanol and ginger extract (GE group), 4- rats group administered ethanol and ginger oil (GO group), 5- rats group administered ethanol and rice bran oil (RBO group) and 6- rats group administered ethanol and DMSO (DMSO control group, because GE, GO and RBO were dissolved in DMSO as a vehicle). Results revealed that hepatic triglycerides was significantly (p≤0.05) raised to 80.7 mg/g liver, in positive control (PC+), compared to 15.98 mg/g liver in normal control (NC). Also significant increase (p≤0.05) in levels of ALT (69.41 U/L), AST (62.98 U/L) and ALP (121.65 U/L) in PC+, compared to their levels in NC (23.35 U/L), (27.95 U/L) and (73.45 U/L) respectively. In addition, high significant level was observed in serum triglycerides (214.37 mg/dl), total cholesterol (TC) (99.81 mg/dl) and LDL cholesterol (47.75 mg/dl) in PC+, compared with its values in NC group: (74.22 mg/dl), (31.45 mg/dl), (4.21 mg/dl) respectively. However, significant (p≤0.05) decrease was noticed in HDL cholesterol level (9.18 mg/dl) in PC+, compared to NC (12.39 mg/dl). On the other hand, treatment by ethanolic ginger extract (200 mg/kg body weight) showed a hepatoprotective effect which confirmed by remediation the values of hepatic TG, ALT, AST, ALP, TP, Alb, besides serum TG, TC, HDL-C and LDL-C in GE group as compared with their values in NC and PC+. Moreover, treatment by ginger oil (200 mg/kg body weight) and rice bran oil (200 mg/kg body weight) displayed a protective effect in GO or RBO groups, but lower than GE. In addition, ethanol extract of ginger disclosed very high antioxidant activity (IC50 = 18.25 µg/ml) compared to both ginger oil (IC50 = 6714.38 µg/ml) or rice bran oil (IC50 = 1409.57 µg/ml). Finally the present study indicates that ethanol extract of ginger showed hepatoprotective effect more than either ginger oil or rice bran oil
Camel Milk Triggers Apoptotic Signaling Pathways in Human Hepatoma HepG2 and Breast Cancer MCF7 Cell Lines through Transcriptional Mechanism
Few published studies have reported the use of crude camel milk in the treatment of stomach infections, tuberculosis and cancer. Yet, little research was conducted on the effect of camel milk on the apoptosis and oxidative stress associated with human cancer. The present study investigated the effect and the underlying mechanisms of camel milk on the proliferation of human cancer cells using an in vitro model of human hepatoma (HepG2) and human breast (MCF7) cancer cells. Our results showed that camel milk, but not bovine milk, significantly inhibited HepG2 and MCF7 cells proliferation through the activation of caspase-3 mRNA and activity levels, and the induction of death receptors in both cell lines. In addition, Camel milk enhanced the expression of oxidative stress markers, heme oxygenase-1 and reactive oxygen species production in both cells. Mechanistically, the increase in caspase-3 mRNA levels by camel milk was completely blocked by the transcriptional inhibitor, actinomycin D; implying that camel milk increased de novo RNA synthesis. Furthermore, Inhibition of the mitogen activated protein kinases differentially modulated the camel milk-induced caspase-3 mRNA levels. Taken together, camel milk inhibited HepG2 and MCF7 cells survival and proliferation through the activation of both the extrinsic and intrinsic apoptotic pathways
Acacia senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity
Cylophosphamide (CYCL) is a strong anticancer and immunosuppressive agent but its urotoxicity presents one of the major toxic effects that limit its wide usage particularly in high dose regimens. Therefore, this study aimed to investigate Acacia Senegal gum exudate, Gum Arabic (GA), for its possible role as a natural, nontoxic agent against CYCL-induced urotoxicity. Male Swiss albino rats were exposed to CYCL (150 mg/kg BW, once i.p) with or without GA oral supplementation (7.5 g/kg/day for 6 days) through drinking water. Glutathione (GSH), Malondialdehyde (MDA) and Nitric oxide (NO) bladder contents were assessed. Responsiveness of the bladder rings to acetylcholine (ACh) in vitro, microscopic and macroscopic features are also investigated. CYCL produced pronounced harmful effects on bladder urothelial lining with significant increases in (MDA) and NO levels in the tissue homogenates. Bladder-GSH content is dropped by over 60% following CYCL injection. Bladder contractility, as measured by its responsiveness to ACh, recorded a marked reduction. The isolated bladders exhibited such macroscopic changes as severe edema, inflammation and extravasation. The bladder weight increased as well. Histological changes were evident in the form of severe congestion, petechial hemorrhage and chronic inflammatory reaction in the lamina propria accompanied with desquamated epithelia. GA, a potential protective agent, produced an almost complete reversal of NO induction, lipid peroxidation or cellular GSH bladder contents in the GA + CYCL-treated group. Likewise, bladder inflammation and edema were reduced. Bladder rings showed a remarkable recovery in their responsiveness to ACh. Bladder histological examination showed a near normal configuration and structural integrity, with a significant reduction in inflammation and disappearance of focal erosions. These remarkable effects of GA may be attributed to its ability to neutralize acrolein, the reactive metabolite of CYCL and/or the resultant reactive oxygen metabolites, through a scavenging action. GA may limit the cascading events of CYCL-induced damage, initiating a cytoprotective effect leading to structural and functional recovery of the bladder tissues
Antimikrobno djelovanje nekih glukopiranozil-pirimidin karbonitrila i fuzioniranih pirimidinskih sustava
3-Amino-5-(4-chlorophenylamino)-4-cyanofuran-2-carboxamide (2) was used as the key molecule for preparation of various furo- pyrimidines 3-9 and formation of spiro-cycloalkane furopyrimidines 10, 11. Also, poly fused heterocyclic compounds 13-17 were prepared from compound 2. The synthesized compounds were screened for their antimicrobial activity.3-Amino-5-(4-klorfenilamino)-4-cijanofuran-2-karboksamid (2) upotrebljen je kao ključni spoj za pripravu različitih furo-pirimidina 3-9 i spiro-cikloalkane furopirimidina 10 i 11. Fuzionirani heterociklički spojevi 13-17 pripravljeni su također polazeći iz spoja 2. Sintetizirani spojevi ispitani su na antimikrobno djelovanje
Characterization of Actinomycetes Antagonist Fusariumoxysporum f.sp.passiflora Isolated from Rhizosphere Soil ofPurple Passion Fruit Plants, South Sulawesi, Indonesia
To survey rhizosphere actinomycetes as potential biocontrol against fungal diseaseof passion fruits, rhizosphere soil of the plant were used as an isolation sources. Twenty fivestrains were assigned to Streptomyces-like strain based on morphological properties of sporechain. Four strain with distinguishing characteristic based on the macroscopic appearance ofcolonies on different media, were recovery from rhizosphere soil of passion fruits plantsuggesting that various Streptomyces spp. grow surrounding of plant roots. On an agarmedium, four strains (11.43%) commonly formed a clear growth-inhibition zone against fungal
pathogen of passion fruits, Fusarium oxysporum f.sp. radicalix passiflori (FORP), indicatingthat this strains can produce antifungal substances. The present results indicate that four strainare a suitable candidate for the biocontrol of fusarium wilt.
Keywords: Actinomycetes, AntifungalFusarium oxysporum f.sp.passiflora Rhizosphere, Purple Passion Fruit Plants, South Sulawesi, Indonesi
Flow analysis from multiparticle azimuthal correlations
We present a new method for analyzing directed and elliptic flow in heavy ion
collisions. Unlike standard methods, it separates the contribution of flow to
azimuthal correlations from contributions due to other effects. The separation
relies on a cumulant expansion of multiparticle azimuthal correlations, and
includes corrections for detector inefficiencies. This new method allows the
measurement of the flow of identified particles in narrow phase-space regions,
and can be used in every regime, from intermediate to ultrarelativistic
energies.Comment: 31 pages, revtex. Published version (references added
Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019 : a systematic analysis for the Global Burden of Disease Study 2020, Release 1
Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health : all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019
Background Sustainable Development Goal 3.2 has targeted elimination of preventable child mortality, reduction of neonatal death to less than 12 per 1000 livebirths, and reduction of death of children younger than 5 years to less than 25 per 1000 livebirths, for each country by 2030. To understand current rates, recent trends, and potential trajectories of child mortality for the next decade, we present the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 findings for all-cause mortality and cause-specific mortality in children younger than 5 years of age, with multiple scenarios for child mortality in 2030 that include the consideration of potential effects of COVID-19, and a novel framework for quantifying optimal child survival.
Methods We completed all-cause mortality and cause-specific mortality analyses from 204 countries and territories for detailed age groups separately, with aggregated mortality probabilities per 1000 livebirths computed for neonatal mortality rate (NMR) and under-5 mortality rate (USMR). Scenarios for 2030 represent different potential trajectories, notably including potential effects of the COVID-19 pandemic and the potential impact of improvements preferentially targeting neonatal survival. Optimal child survival metrics were developed by age, sex, and cause of death across all GBD location-years. The first metric is a global optimum and is based on the lowest observed mortality, and the second is a survival potential frontier that is based on stochastic frontier analysis of observed mortality and Healthcare Access and Quality Index.
Findings Global U5MR decreased from 71.2 deaths per 1000 livebirths (95% uncertainty interval WI] 68.3-74-0) in 2000 to 37.1 (33.2-41.7) in 2019 while global NMR correspondingly declined more slowly from 28.0 deaths per 1000 live births (26.8-29-5) in 2000 to 17.9 (16.3-19-8) in 2019. In 2019,136 (67%) of 204 countries had a USMR at or below the SDG 3.2 threshold and 133 (65%) had an NMR at or below the SDG 3.2 threshold, and the reference scenario suggests that by 2030,154 (75%) of all countries could meet the U5MR targets, and 139 (68%) could meet the NMR targets. Deaths of children younger than 5 years totalled 9.65 million (95% UI 9.05-10.30) in 2000 and 5.05 million (4.27-6.02) in 2019, with the neonatal fraction of these deaths increasing from 39% (3.76 million [95% UI 3.53-4.021) in 2000 to 48% (2.42 million; 2.06-2.86) in 2019. NMR and U5MR were generally higher in males than in females, although there was no statistically significant difference at the global level. Neonatal disorders remained the leading cause of death in children younger than 5 years in 2019, followed by lower respiratory infections, diarrhoeal diseases, congenital birth defects, and malaria. The global optimum analysis suggests NMR could be reduced to as low as 0.80 (95% UI 0.71-0.86) deaths per 1000 livebirths and U5MR to 1.44 (95% UI 1-27-1.58) deaths per 1000 livebirths, and in 2019, there were as many as 1.87 million (95% UI 1-35-2.58; 37% [95% UI 32-43]) of 5.05 million more deaths of children younger than 5 years than the survival potential frontier.
Interpretation Global child mortality declined by almost half between 2000 and 2019, but progress remains slower in neonates and 65 (32%) of 204 countries, mostly in sub-Saharan Africa and south Asia, are not on track to meet either SDG 3.2 target by 2030. Focused improvements in perinatal and newborn care, continued and expanded delivery of essential interventions such as vaccination and infection prevention, an enhanced focus on equity, continued focus on poverty reduction and education, and investment in strengthening health systems across the development spectrum have the potential to substantially improve USMR. Given the widespread effects of COVID-19, considerable effort will be required to maintain and accelerate progress
Global burden of 87 risk factors in 204 countries and territories, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019
Background Rigorous analysis of levels and trends in exposure to leading risk factors and quantification of their effect on human health are important to identify where public health is making progress and in which cases current efforts are inadequate. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a standardised and comprehensive assessment of the magnitude of risk factor exposure, relative risk, and attributable burden of disease.
Methods GBD 2019 estimated attributable mortality, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 87 risk factors and combinations of risk factors, at the global level, regionally, and for 204 countries and territories. GBD uses a hierarchical list of risk factors so that specific risk factors (eg, sodium intake), and related aggregates (eg, diet quality), are both evaluated. This method has six analytical steps. (1) We included 560 risk-outcome pairs that met criteria for convincing or probable evidence on the basis of research studies. 12 risk-outcome pairs included in GBD 2017 no longer met inclusion criteria and 47 risk-outcome pairs for risks already included in GBD 2017 were added based on new evidence. (2) Relative risks were estimated as a function of exposure based on published systematic reviews, 81 systematic reviews done for GBD 2019, and meta-regression. (3) Levels of exposure in each age-sex-location-year included in the study were estimated based on all available data sources using spatiotemporal Gaussian process regression, DisMod-MR 2.1, a Bayesian meta-regression method, or alternative methods. (4) We determined, from published trials or cohort studies, the level of exposure associated with minimum risk, called the theoretical minimum risk exposure level. (5) Attributable deaths, YLLs, YLDs, and DALYs were computed by multiplying population attributable fractions (PAFs) by the relevant outcome quantity for each age-sex-location-year. (6) PAFs and attributable burden for combinations of risk factors were estimated taking into account mediation of different risk factors through other risk factors. Across all six analytical steps, 30 652 distinct data sources were used in the analysis. Uncertainty in each step of the analysis was propagated into the final estimates of attributable burden. Exposure levels for dichotomous, polytomous, and continuous risk factors were summarised with use of the summary exposure value to facilitate comparisons over time, across location, and across risks. Because the entire time series from 1990 to 2019 has been re-estimated with use of consistent data and methods, these results supersede previously published GBD estimates of attributable burden.
Findings The largest declines in risk exposure from 2010 to 2019 were among a set of risks that are strongly linked to social and economic development, including household air pollution; unsafe water, sanitation, and handwashing; and child growth failure. Global declines also occurred for tobacco smoking and lead exposure. The largest increases in risk exposure were for ambient particulate matter pollution, drug use, high fasting plasma glucose, and high body-mass index. In 2019, the leading Level 2 risk factor globally for attributable deaths was high systolic blood pressure, which accounted for 10.8 million (95% uncertainty interval [UI] 9.51-12.1) deaths (19.2% [16.9-21.3] of all deaths in 2019), followed by tobacco (smoked, second-hand, and chewing), which accounted for 8.71 million (8.12-9.31) deaths (15.4% [14.6-16.2] of all deaths in 2019). The leading Level 2 risk factor for attributable DALYs globally in 2019 was child and maternal malnutrition, which largely affects health in the youngest age groups and accounted for 295 million (253-350) DALYs (11.6% [10.3-13.1] of all global DALYs that year). The risk factor burden varied considerably in 2019 between age groups and locations. Among children aged 0-9 years, the three leading detailed risk factors for attributable DALYs were all related to malnutrition. Iron deficiency was the leading risk factor for those aged 10-24 years, alcohol use for those aged 25-49 years, and high systolic blood pressure for those aged 50-74 years and 75 years and older.
Interpretation Overall, the record for reducing exposure to harmful risks over the past three decades is poor. Success with reducing smoking and lead exposure through regulatory policy might point the way for a stronger role for public policy on other risks in addition to continued efforts to provide information on risk factor harm to the general public
- …